Jan Hillert, MD, PhD, professor and senior physician in the department of clinical neuroscience, Karolinska Institutet, Stockholm, Sweden, discusses the body of knowledge on using stem cell transplants to treat patients with multiple sclerosis (MS).
Jan Hillert, MD, PhD, professor and senior physician in the department of clinical neuroscience, Karolinska Institutet, Stockholm, Sweden, discusses the body of knowledge on using stem cell transplants to treat patients with multiple sclerosis (MS).
Transcript
What is the current state of knowledge about using stem cell transplants in patients with MS?
There is an increasing body of evidence indicating that the effectiveness of such procedures is very good. The proportion of patients having gone through such a procedure having no evidence of disease activity, what we can NEDA, is unparalleled by other ways of treating MS. So for sure, this is a very efficient way of stopping the relapsing form of MS.
Whether it also prevents the progressive phase, which comes long after, we don’t know yet. We know that if we do the transplants when the patient is already in the progressive phase, then the progression carries on, so we need to do it early.
The remaining issue which prevents this from being very, very widespread is of course the safety side. It looks really promising. In some of the regiments, some of the ways in which to do this, there have been very few side effects and practically no mortality. Whereas in some of the other ways of doing it, there are still people dying from the procedure itself. So we need to ensure, of course, if we launch this as a treatment for a big proportion of MS patients, that it’s really safe.
Then the question ethically becomes, what kind of mortality can we accept? It needs to be way below a percent, of course. So that’s why there is still hesitation, I would say. But the efficacy or effectiveness evidence, they look just fantastic.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More